Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-GARP CAR T Cell Therapy in Recurrent High-Grade Glioma
NCT06964737Phase 1Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-GARP CAR T cells in glioma, sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Dose Limiting Toxicities at 30 days. Started May 2025; status: recruiting.
02
Drugs
anti-GARP CAR T cells
03
Conditions
glioma
Beyond the preview
Go deeper on NCT06964737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06964737.